<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01774760</url>
  </required_header>
  <id_info>
    <org_study_id>T14/2013</org_study_id>
    <nct_id>NCT01774760</nct_id>
  </id_info>
  <brief_title>Reproducibility of Intratumor Distribution of 18F-EF5 in Head and Neck Cancer</brief_title>
  <official_title>Reproducibility of Intratumor Distribution of 18F-EF5 in Head and Neck Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Turku University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Turku University Hospital</source>
  <brief_summary>
    <textblock>
      The results of previous studies suggest further development of [18F]EF5 as a PET tracer for
      imaging hypoxia. This is a non-randomized prospective study to obtain information on
      reproducibility of [18F]EF5 intratumor distribution using repeated pretreatment PET/CT scans.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients will undergo normal diagnostic and staging procedures, including a conventional
      18F-FDG PET/CT scan for the purpose of RT or surgical planning. In addition to that, an
      18F-EF5 PET/CT scan will be performed on a separate day. The patients receive intravenous
      injection of 250-350 MBq of [18F]EF5. After that, a venous blood sample will be obtained for
      measurement of plasma radioactivity. A low-dose CT (helical) will be performed for
      attenuation correction and anatomical reference. After that, a PET scan will be performed
      (starting at 3 h after injection). The second 18F-EF5 scan will be performed in a similar way
      4-7 days after the first scan. A representative histologic sample of primary tumor is
      pre-condition for study and an effort is made to store part of fresh histologic material in
      liquid nitrogen for later use in immunohistochemical analysis.

      Patients are scheduled to undergo preoperative or definitive chemoradiotherapy using current
      clinical standards after completion of the current protocol. Follow-up information
      (event-free survival and overall survival) will be gathered.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in 18F-EF5 Standardized Uptake Values (SUV)</measure>
    <time_frame>Baseline and 7 days (ie time between the two scans)</time_frame>
    <description>Standardized Uptake Values (SUV) are determined in the acquisition images of the [18F]EF5 studies.The difference between the baseline and second SUV is calculated and Bland-Altman plots are generated to compare the group means</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Squamous Cell Carcinoma of the Head and Neck</condition>
  <arm_group>
    <arm_group_label>Patients with stage III-IV head and neck cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>18F-EF5 PET/CT scan</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>18F-EF5</intervention_name>
    <arm_group_label>Patients with stage III-IV head and neck cancer</arm_group_label>
    <other_name>PET/CT static imaging</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pretreatment PET/CT-scan (performed two times)</intervention_name>
    <arm_group_label>Patients with stage III-IV head and neck cancer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Performance status: Karnofsky score 70 or better or WHO performance status 2 or better

          -  Diagnosis: Histological, cytological and clinical findings are consistent with
             squamous cell carcinoma of the head and neck

          -  Primary tumor diameter as determined clinically or from contrast enhanced CT or
             T1-weighed MRI scan must be at least 15 mm

          -  Patients with nodal neck metastases of head and neck cancer are eligible

          -  Mental status: Patients must be able to understand the meaning of the study

          -  The patient must sign the appropriate Ethical Committee (EC) approved informed consent
             documents in the presence of the designated staff

          -  Patient, if female, must not be pregnant or lactating at the time of the study

        Exclusion Criteria:

          -  Patient must have no history of serious haematologic, cardiovascular, liver or kidney
             disease.

          -  Patient must have no history of previous chemotherapy or biological therapy or RT for
             treatment of head and neck cancer.

          -  Patient must not have an uncontrolled serious infection

          -  Patients with organ metastases in liver, bone, brain or lung.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heikki Minn, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Turku University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Turku University Hospital</name>
      <address>
        <city>Turku</city>
        <zip>FI-20521</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>January 21, 2013</study_first_submitted>
  <study_first_submitted_qc>January 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2013</study_first_posted>
  <results_first_submitted>February 28, 2019</results_first_submitted>
  <results_first_submitted_qc>September 13, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 4, 2019</results_first_posted>
  <last_update_submitted>September 13, 2019</last_update_submitted>
  <last_update_submitted_qc>September 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Turku University Hospital</investigator_affiliation>
    <investigator_full_name>Heikki Minn</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>18F-EF5</keyword>
  <keyword>PET/CT</keyword>
  <keyword>Reproducibility</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>11 were recruited, 10 started and completed</recruitment_details>
      <pre_assignment_details>1 patient withdrawn because of a negative FDG PET scan</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>18F-EF5 PET/CT Scan</title>
          <description>18F-EF5
Pretreatment PET/CT-scan (performed two times)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>18F-EF5 PET/CT Scan</title>
          <description>10 pts with HNSCC. See Table 1 (p. 163) in Eur J Nucl Med Mol Imaging 2018;45:161-169 https://doi.org/10.1007/s00259-017-3857-3</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Finland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in 18F-EF5 Standardized Uptake Values (SUV)</title>
        <description>Standardized Uptake Values (SUV) are determined in the acquisition images of the [18F]EF5 studies.The difference between the baseline and second SUV is calculated and Bland-Altman plots are generated to compare the group means</description>
        <time_frame>Baseline and 7 days (ie time between the two scans)</time_frame>
        <population>Head and neck squamous cell carcinoma</population>
        <group_list>
          <group group_id="O1">
            <title>Patients With Stage III-IV Head and Neck Cancer</title>
            <description>Patients undergoing radiation treatment planning who receive pretreatment PET/CT-scan twice within 1 week as an experimental procedure</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 18F-EF5 Standardized Uptake Values (SUV)</title>
          <description>Standardized Uptake Values (SUV) are determined in the acquisition images of the [18F]EF5 studies.The difference between the baseline and second SUV is calculated and Bland-Altman plots are generated to compare the group means</description>
          <population>Head and neck squamous cell carcinoma</population>
          <units>SUVmax</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.49" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>18F-EF5 PET/CT Scan</title>
          <description>18F-EF5
Pretreatment PET/CT-scan (performed two times)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Prof. Heikki Minn</name_or_title>
      <organization>Turku University Hospital, Turku, Finland</organization>
      <phone>+35823130000 ext 30149</phone>
      <email>heikki.minn@tyks.fi</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

